In stock🧪 Certificate with every lotSynthos Reta 40 mg pen
Weight management

Reta 40 mg pen

Retatrutide

Triple GLP-1 / GIP / glucagon receptor agonist in a ready-to-use pre-filled pen.

€279€0 today. Pay after a quick
confirmation call · ships in 1–2 days
1
Read the full Reta guide
🧪Certificate of analysis for your lot
💬A real person confirms first
🇪🇺Ships from the EU, no customs in the EU
📦Plain, discreet, tracked box
Overview

Retatrutide is a next-generation triple agonist acting on the GLP-1, GIP and glucagon receptors, often nicknamed “GLP-3”. In a 48-week phase 2 trial published in the New England Journal of Medicine (2023), the highest dose was associated with an average 24.2% reduction in body weight. Phase 3 TRIUMPH trials reporting in 2025–2026 found average losses of up to 28.7% on the top dose. It is still under clinical investigation and not yet approved.

Read our full research review →
Research focus
  • Appetite and satiety signalling
  • Energy expenditure via the glucagon receptor
  • Comparison with single and dual agonists
Specifications
CompoundRetatrutide
Amount40 mg pen
FormReady-to-use pre-filled pen
In the boxBranded Synthos box with one pre-filled 40 mg pen and 12 pen needles. No reconstitution required.
QualityIndependent lab test, certificate of analysis per lot
StorageStorage instructions are included in the box
UseLaboratory research only
Shipping & payment

Tracked shipping worldwide from inside the EU: 2–5 working days with no customs inside the EU, usually 5–12 working days elsewhere. Nothing is charged online: a representative contacts you within 24 hours to confirm your order, then you pay by card, bank transfer or a local method. More details

For laboratory research use only. Not a medicine and not for human or veterinary use. Not approved by the EMA, FDA or any other regulator. Sold to adults 18+.

TyrAibGlnGlyThrPheThrSerAspTyrSerIleα-MeLeuLeuAspLysLys(AEEA-γGlu-C20 diacid)AlaGlnAibAlaPheIleGluTyrLeuLeuGluGlyGlyProSerSerGlyAlaProProProSer
The research behind this product

Retatrutide: what the triple-hormone trials actually show

One molecule, three hormone receptors and a phase 3 programme of more than 5,800 people. Here is what the retatrutide data say about weight, liver fat and side effects, and what they still cannot tell us.

Read the review 10 min read · 15 references
How ordering works

Nothing to pay online

No account and no card. You leave your number, a real person calls, and you pay only once everything is clear.

  1. Add to cart

    Choose the quantity. Nothing is charged.

  2. Leave your number

    Name and phone at checkout, about 30 seconds.

  3. We call you

    Within 24 hours, by phone or WhatsApp. Ask for the lot certificate.

  4. Pay & receive

    Card, transfer or a local method. Tracked box from the EU.

You may also like

Related products

More in Weight management
BestsellerSynthos Reta 10 mg
Weight managementReta 10 mg

Triple GLP-1 / GIP / glucagon receptor agonist, 10 mg lyophilised peptide vial.

€89
Synthos Cagrilintide 10 mg
Weight managementCagrilintide 10 mg

Long-acting amylin analogue studied in appetite regulation.

€125
Synthos 5-Amino-1MQ 10 mg
Weight management5-Amino-1MQ 10 mg

Small-molecule NNMT inhibitor studied in fat-cell metabolism.

€65
Synthos AOD-9604 10 mg
Weight managementAOD-9604 10 mg

Modified fragment of the growth-hormone C-terminus studied in fat metabolism.

€110
Reta 40 mg pen€279